Thompson Ian M
Department of Urology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA.
J Urol. 2006 Dec;176(6 Pt 2):S21-4; discussion S25-6. doi: 10.1016/j.juro.2006.06.078.
Risk stratification is commonly used in patients with prostate cancer but this effort has had no demonstrable effect on patient decision making for initial therapy. We propose new risk strata for clinically localized prostate cancer.
We examined current stratification methods for prostate cancer and their impact on prostate cancer therapy.
Three risk strata for patients with clinically localized prostate cancer are proposed. Stratum 1 includes patients in whom active surveillance is associated with a low risk of disease progression. Stratum 2 includes patients in whom monotherapy, including external beam, interstitial radiotherapy or radical prostatectomy, is generally successful. Stratum 3 includes patients at high risk for recurrence with monotherapy in whom multimodal therapy may be superior.
Risk stratification systems for prostate cancer should harmonize the needs of researchers to develop comparable groupings of patients, of patients who seek guidance on optimal therapy and of clinical trialists who seek to advance therapy for this disease. Our new stratification system provides such a structure.
风险分层常用于前列腺癌患者，但这一举措对患者初始治疗的决策制定并无明显影响。我们提出了临床局限性前列腺癌的新风险分层。
我们研究了当前前列腺癌的分层方法及其对前列腺癌治疗的影响。
提出了临床局限性前列腺癌患者的三个风险分层。第1层包括积极监测与疾病进展低风险相关的患者。第2层包括单一疗法（包括外照射、间质放疗或根治性前列腺切除术）通常成功的患者。第3层包括单一疗法复发风险高且多模式疗法可能更优的患者。
前列腺癌风险分层系统应兼顾研究人员对患者进行可比分组的需求、寻求最佳治疗指导的患者的需求以及寻求推进该疾病治疗的临床试验人员的需求。我们的新分层系统提供了这样一种结构。
